Grünenthal Selects BioClinica OnPoint Clinical Trial Management System

– Leading Pain Management Company Standardizes on BioClinica CTMS Technology –

March 5, 2012.  NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that Grünenthal GmbH has signed a global license agreement for BioClinica OnPoint CTMS to support its ongoing clinical trials. BioClinica OnPoint CTMS helps clinical trial sponsors to easily consolidate their data, share this data and improve trial management by using Microsoft SharePoint 2010 and Microsoft Office 2010.

Grünenthal selected BioClinica OnPoint after a thorough evaluation of the leading enterprise-scale CTMS solutions. The assessment team was comprised of Grünenthal experts from various functional areas. The workshops demonstrated that the requirements specified by Grünenthal could be delivered faster and most cost-effectively using OnPoint. Grünenthal was particularly impressed with BioClinica's ability to integrate with other clinical systems, the extensibility of this consolidated data via SharePoint-based dashboards and the fact that OnPoint allows clinical staff to do much of their work within the familiar environment of Microsoft Office applications.

"After careful review of the commercially available CTMS solutions, we felt that BioClinica's platform provides our clinical staff with a timely and comprehensive overview of relevant data and thus helps to make planning more efficient," said Hazel Collie, Head of Quality & Systems at Grünenthal. "In this regard, OnPoint supports our objective to enhance our innovation process, allowing us to develop solutions to improve the quality of life of our patients."

"Life sciences companies of all sizes face increased pressure to efficiently manage clinical trials while bringing drugs to market quickly," said Andrea McGonigle, managing director, Life Sciences, Microsoft Corp. "BioClinica uses Microsoft SharePoint and Office to help clients gain a comprehensive, real-time view into trial performance and act on that information."

Mark Weinstein, CEO of BioClinica, said, "We are proud to be selected to support Grünenthal's clinical trial support needs, world-wide. This agreement demonstrates the results of our continuing commitment to deliver innovative technology solutions that help customers execute and manage their clinical trials with greater efficiency and speed."

About the Grünenthal Group
The Grünenthal Group is an independent, family-owned international research based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain, its objective is to become the most patient-centric company and to be a leader in therapy innovation. Altogether, the Grünenthal Group has affiliates in 30 countries worldwide. Grünenthal products are sold in more than 150 countries and approx. 4,500 employees are working for the Grünenthal Group globally. In 2010, Grünenthal reached revenues of about 910M €. For more information: www.grunenthal.com.

About BioClinica, Inc.
BioClinica accelerates the development of new medical therapies by delivering expertise and technologies that enhance clinical research, worldwide. Our industry-leading medical imaging services, cardiac safety, and enterprise eClinical platform bring a new level of quality and efficiency to every phase of clinical development. Our experience spans three decades and includes thousands of studies in all therapeutic areas, from design and management, through submission and post-approval. BioClinica serves more than 400 pharmaceutical, biotechnology, and device companies – including all the top 20 - through a network of offices in the U.S., Europe, and Asia.